Avalo Therapeutics (AVTX) Operating Margin (2016 - 2024)
Historic Operating Margin for Avalo Therapeutics (AVTX) over the last 10 years, with Q4 2024 value amounting to 6932.81%.
- Avalo Therapeutics' Operating Margin fell 55916600.0% to 6932.81% in Q4 2024 from the same period last year, while for Sep 2025 it was 34632.29%, marking a year-over-year decrease of 269663200.0%. This contributed to the annual value of 15535.6% for FY2024, which is 141140300.0% down from last year.
- As of Q4 2024, Avalo Therapeutics' Operating Margin stood at 6932.81%, which was down 55916600.0% from 5165.06% recorded in Q3 2024.
- In the past 5 years, Avalo Therapeutics' Operating Margin registered a high of 27.39% during Q3 2022, and its lowest value of 8202.28% during Q4 2021.
- Moreover, its 5-year median value for Operating Margin was 1207.27% (2020), whereas its average is 2365.68%.
- In the last 5 years, Avalo Therapeutics' Operating Margin plummeted by -71108300bps in 2021 and then skyrocketed by 72140000bps in 2022.
- Quarter analysis of 5 years shows Avalo Therapeutics' Operating Margin stood at 1091.45% in 2020, then crashed by -652bps to 8202.28% in 2021, then soared by 88bps to 988.28% in 2022, then crashed by -36bps to 1341.16% in 2023, then crashed by -417bps to 6932.81% in 2024.
- Its last three reported values are 6932.81% in Q4 2024, 5165.06% for Q3 2024, and 1341.16% during Q4 2023.